137421-53-5

Basic information

• Product Name: methyl 3,5-diallyl-4-hydroxybenzoate
• Synonyms: methyl 3,5-diallyl-4-hydroxybenzoate
• CAS NO: 137421-53-5
• Molecular Weight: 232.279
• Mol File: 137421-53-5.mol

Chemical Properties

• CAS DataBase Reference: methyl 3,5-diallyl-4-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3,5-diallyl-4-hydroxybenzoate(137421-53-5)
• EPA Substance Registry System: methyl 3,5-diallyl-4-hydroxybenzoate(137421-53-5)

Safety Data

• Hazardous Substances Data: 137421-53-5(Hazardous Substances Data)

Upstream product

• 137421-52-4 methyl 3-(2-propenyl)-4-(2-propenyloxy)benzoate 
• 53596-60-4 methyl 3-allyl-4-hydroxybenzoate 
• 35750-24-4 methyl 4-allyloxybenzoate 
• 99-76-3 methyl 4-hydroxylbenzoate 

Downstream Products

• 153275-21-9 [4-(2-Ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-2,6-dipropyl-phenoxy]-m-tolyl-acetic acid ethyl ester 

Relevant articles and documents

N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY

Novel N-hydroxyamide derivatives are disclosed. These N-hydroxyamide derivatives inhibit UPD-3O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, an enzyme present in gram negative bacteria and are therefore useful as antimicrobials and antibiotics. Methods of synthesis and of use of the compounds are also disclosed.

Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives

Phenoxyphenylacetic acids and derivatives of general structural formula I have endothelin STR1 antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, congestive heart failure, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, inflammatory diseases, Raynaud's disease, and endotoxic shock, and asthma.

SIX MEMBERED RING FUSED IMIDAZOLES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES USED TO TREAT ASTHMA

Phenoxyphenylacetic acids and derivatives of general structural formula I STR1 have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, congestive heart failure, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, inflammatory diseases, Raynaud's disease, and endotoxic shock, and asthma.

QUINOLINE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT

Substituted quinolines and azaquinolines (1,5-naphthridines) attached through an oxymethylene bridge to novel substituted phenyl derivatives of the Formula I, are useful as angiotensin II antagonists. STR1

ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED PYRIDOIMIDAZOLYL RING

Substituted heterocycles attached through a methylene bridge to novel substituted phenyl derivatives of the Formula I are useful as angiotensin II antagonists. STR1